Literature DB >> 9282944

Selective aggregation of endogenous beta-amyloid peptide and soluble amyloid precursor protein in cerebrospinal fluid by zinc.

A M Brown1, D M Tummolo, K J Rhodes, J R Hofmann, J S Jacobsen, J Sonnenberg-Reines.   

Abstract

Zinc added to buffered solutions of synthetic beta-amyloid peptide (A beta) has been reported to induce accelerated formation of insoluble aggregates. This observation suggests that zinc may play a role in the formation of senile plaques, which contain A beta, in Alzheimer's disease. To test this hypothesis under conditions more representative of the brain, we investigated the ability of zinc to induce aggregation of A beta in freshly drawn canine CSF, which contains the same sequence as human A beta. Aggregates were separated from CSF by ultracentrifugation before and after incubation with zinc and assayed by quantitative western blotting and ELISA. We found that zinc induced the rapid aggregation of endogenous A beta in CSF, with an EC50 of 120-140 microM. The reaction was specific, because most (> or = 95%) CSF protein remained soluble under conditions where most A beta was insoluble, as assayed by scanning densitometry of Coomassie-stained gels. Staining of the precipitated material resulted in the visualization of punctate regions that were thioflavin positive or birefringent when stained with Congo red, suggesting the formation of amyloid-related structures. These results suggest that zinc could play a role in amyloid deposition, because there is overlap between the regions of the brain where zinc concentrations are highest and regions with the highest amyloid content. It is surprising that zinc induced the aggregation of endogenous soluble APP at lower concentrations than required for A beta (EC50 80 microM). The possibility that zinc-induced aggregation of APP may precede the deposition of A beta into plaques is discussed. Investigation of aggregation of A beta in CSF will aid in assessing the biological relevance of other agents that have been reported to accelerate amyloid formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9282944     DOI: 10.1046/j.1471-4159.1997.69031204.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

Review 1.  Meeting of the minds: metalloneurochemistry.

Authors:  Shawn C Burdette; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

2.  Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid.

Authors:  Dorothea Strozyk; Lenore J Launer; Paul A Adlard; Robert A Cherny; Andrew Tsatsanis; Irene Volitakis; Kaj Blennow; Helen Petrovitch; Lon R White; Ashley I Bush
Journal:  Neurobiol Aging       Date:  2007-12-18       Impact factor: 4.673

3.  Upregulation of zinc transporter 2 in the blood-CSF barrier following lead exposure.

Authors:  Xue Fu; Andrew Zeng; Wei Zheng; Yansheng Du
Journal:  Exp Biol Med (Maywood)       Date:  2013-12-05

4.  Longitudinal changes in zinc transport kinetics, metallothionein and zinc transporter expression in a blood-brain barrier model in response to a moderately excessive zinc environment.

Authors:  Dennis J Bobilya; Nicole A Gauthier; Shakun Karki; Bryony J Olley; W Kelly Thomas
Journal:  J Nutr Biochem       Date:  2007-12-03       Impact factor: 6.048

Review 5.  Pharmacotherapeutic targets in Alzheimer's disease.

Authors:  Yif'at Biran; Colin L Masters; Kevin J Barnham; Ashley I Bush; Paul A Adlard
Journal:  J Cell Mol Med       Date:  2008-11-18       Impact factor: 5.310

6.  Zinc Status Alters Alzheimer's Disease Progression through NLRP3-Dependent Inflammation.

Authors:  Jack Rivers-Auty; Victor S Tapia; Claire S White; Michael J D Daniels; Samuel Drinkall; Paul T Kennedy; Harry G Spence; Shi Yu; Jack P Green; Christopher Hoyle; James Cook; Amy Bradley; Alison E Mather; Ruth Peters; Te-Chen Tzeng; Margaret J Gordon; John H Beattie; David Brough; Catherine B Lawrence
Journal:  J Neurosci       Date:  2021-02-17       Impact factor: 6.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.